<i>In Vitro</i> Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program
James A. Karlowsky, Meredith Hackel, Gregory G. Stone, Daniel F. Sahm
Abstract
Ceftibuten is an established, oral, third-generation cephalosporin in early clinical development in combination with an oral prodrug of avibactam for the treatment of complicated urinary tract infections, including acute pyelonephritis. We evaluated the in vitro activity of ceftibuten-avibactam against 1,165 Enterobacterales isolates selected from the 2016–2020 ATLAS global surveillance program based upon their β-lactamase genotype, β-lactam-susceptible phenotype, species identification, and specimen source (95.8% urine).
Topics & Concepts
AvibactamCephalosporinProdrugCeftazidime/avibactamMedicineCarbapenemUrinary systemIn vitroMicrobiologyAntibioticsChemistryPharmacologyEnterobacteriaceaeBiologyInternal medicineEscherichia coliBiochemistryGeneAntibiotic Resistance in BacteriaUrinary Tract Infections ManagementAntibiotics Pharmacokinetics and Efficacy